Prana Biotechnology Ltd.'s dreams of becoming a late-stage drug development company in 2005 suffered a blow Monday with the company's decision to cancel an upcoming Phase II/III trial of PBT1, a disease-modifying compound for Alzheimer's disease, due to manufacturing toxicity issues. (BioWorld International)

Northfield Laboratories Inc.'s stock jumped 31.6 percent Monday after an independent data monitoring committee gave the go-ahead for the ongoing Phase III trial of PolyHeme. (BioWorld Today)